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DOI 10.1016/j.ccr.2011.04.002SUMMARYWe have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras onco-
gene-driven non-small cell lung carcinoma (NSCLC). Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing
lung cells had no significant effect due to compensatory activities. Yet, elimination of both Erk kinases
completely blocked tumor development. Similar results were obtained with Mek kinases. Ablation of B-Raf
had no significant effect on tumor development. However, c-Raf expression was absolutely essential
for the onset of NSCLC. Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no
deleterious consequences for normal homeostasis. These results indicate that c-Raf plays a unique role in
mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.INTRODUCTION
Ras proteins are small GTPases that serve as mitogenic
switches to convey information generated at the cell surface to
the nuclear transcriptional machinery through multiple effector
cascades. These proteins have been extensively characterized
at the structural, biochemical, and cellular level due to their
central role in eukaryotic biology, as well as their implication in
cancer development (Malumbres and Barbacid, 2003; Karnoub
and Weinberg, 2008). To date, multiple Ras downstream
effectors have been identified. It is generally accepted that the
Raf/Mek/Erk cascade of kinases is the primary mediator of
mitogenic activity (Marshall, 1994). Another well-known
pathway, the PI3Kinase/Pdk/Akt pathway, is thought to mediate
survival signals (Cully et al., 2006; Engelman et al., 2006). OtherSignificance
K-RAS oncogenes have been implicated in one-fourth of no
tumors with the worst prognosis. Although K-RAS signals th
MEK1/2, and ERK1/2 kinases, to our knowledge, it is not know
ment. Here, we demonstrate that ablation of Mek1/2 or Erk1/2
their systemic elimination is incompatible with adult life. In co
NSCLC without inducing deleterious effects when systemicall
with B-Raf. These observations point to c-RAF as a suitable ta
652 Cancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc.Ras effectors include the GDP/GTP exchange factors Tiam1 and
RalGDS, which are responsible for activating other families of
small GTPases involved in the control of cell polarity and motility
as well as membrane trafficking (Malliri and Collard, 2003;
Camonis and White, 2005). Other downstream effectors such
as PLCe, AF6, Rin1, and RASSF have been less extensively
characterized.
Despite this wealth of information, little is known about the
precise pathways that mediate RAS oncogenic signaling in
cancer. K-RAS, the RAS oncogene most frequently mutated in
human cancer, has been implicated in a variety of tumor types
including non-small cell lung carcinoma (NSCLC), one of the
tumors with the worst prognosis and for which, to our knowl-
edge, there are no effective treatments (Malumbres and Barba-
cid, 2003; Karnoub and Weinberg, 2008). Genetic studies inn-small cell lung carcinomas (NSCLCs), one of the human
rough a cascade of druggable kinases including the RAF,
n how these individual kinases contribute to tumor develop-
kinases completely prevents tumor development, although
ntrast, ablation of c-Raf completely prevents K-Ras-driven
y eliminated in adult tissues, either alone or in combination
rget for therapeutic intervention in K-RAS-driven NSCLC.
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Figure 1. K-RasG12V Induces NSCLCs in the Absence of Erk1 or Erk2
(A) The left panel shows survival of K-Ras+/G12V;Erk1+/+ (n = 17) (open circles)
and K-Ras+/G12V;Erk1/ (n = 14) (solid circles) mice treated with Ad-Cre
at 8 weeks of age. The right panel illustrates survival of K-Ras+/G12V;Erk2+/+
(n = 19) (open circles) and K-Ras+/G12V;Erk2lox/lox (n = 32) (solid circles) mice
treated with Ad-Cre at 8 weeks of age.
(B) The left panel shows the number of tumors, classified by grade (I–IV),
observed in K-Ras+/G12V;Erk1+/+ (n = 5) (open bars) and K-Ras+/G12V;Erk1/
(n = 5) (solid bars) mice sacrificed 6 months after Ad-Cre treatment. The right
panel illustrates the number of tumors, classified by grade (I–IV), observed in
K-Ras+/G12V;Erk2+/+ (n = 5) (open bars) and K-Ras+/G12V;Erk2lox/lox (n = 5) (solid
bars) mice sacrificed 6 months after Ad-Cre treatment. Error bars indicate
mean ± SD. p values were calculated according to Student’s t test.
(C) Western blot analysis of pErk1/2, Erk1/2, pRsk, and Rsk expression in
lysates prepared from individual tumors of the indicated genotype collected
8 months after Ad-Cre treatment. Gapdh is shown as a loading control.
Migration of the above proteins is indicated by arrowheads.
See also Figure S1.
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c-Raf, A Therapeutic Target for K-Ras-Driven NSCLCmouse models of NSCLC (Johnson et al., 2001) have indicated
that K-Ras may signal through the PI3Kinase/Akt pathway.
Mice carrying a germline mutation in the alpha subunit of PI3Ki-
nase that prevents interaction with Ras proteins developed
significantly fewer lung tumors than control mice (Gupta et al.,
2007). Ablation of the two loci encoding the p85 regulatory
subunits of PI3Kinase also resulted in significant reduction of
the number of tumors appearing in the same tumor model
(Engelman et al., 2008). More recently, new therapeutic targets,
including the NF-kB pathway and the cell cycle kinase Cdk4,
have been identified by synthetic lethal approaches (Meylan
et al., 2009; Puyol et al., 2010). Other potential targets identifiedby in vitro screens include the noncanonical IkB kinase, Tbk1,
and the mitotic PLK1 kinase (Barbie et al., 2009; Luo et al.,
2009). Interestingly, there is little information on the distinct
contributions of the Raf/Mek/Erk kinases to K-Ras-induced
NSCLC.
We undertook the present study to systematically examine by
genetic means the contribution of the Raf/Mek/Erk cascade of
kinases in a mouse model of K-Ras-driven NSCLC (Guerra
et al., 2003). To this end, we have used strains of mice carrying
mutations within loci encoding Raf, Mek, and Erk kinases to
investigate whether they are essential for tumor development.
The results described below provide information that might
be used in the future to design targeted therapies to block
K-RAS-induced NSCLC in human patients.
RESULTS
Elimination of Individual Erk Kinases Does Not Prevent
K-RasG12V-Induced NSCLCs
We investigated whether the Erk kinases, Erk1 and Erk2, were
necessary for the induction of NSCLC mediated by a resident
K-RasG12V oncogene. K-Ras+/LSLG12Vgeo mice (designated from
now on as K-Ras+/G12V) (Guerra et al., 2003) were crossed to
strains carrying mutated alleles of Erk1 (Erk1/) and Erk2
(Erk2 lox/lox) (Page`s et al., 1999; Fischer et al., 2005). Eight-
week-old K-Ras+/G12V;Erk1/ and K-Ras+/G12V;Erk2 lox/lox mice,
along with control animals, were exposed by intratracheal instil-
lation to replication-defective adenoviruses encoding the Cre re-
combinase (Ad-Cre). This strategy allowed expression of the
resident K-RasG12V oncoprotein in the infected lung cells upon
Cre-mediated recombination of the floxed stop cassette inserted
within the K-Ras locus (Guerra et al., 2003). In addition the Cre
recombinase also ablated the Erk2lox alleles in those cells
expressing the K-RasG12V oncogene.
Absence of either Erk1 or Erk2 resulted in limited increase of
the lifespan of these animals (Figure 1A) . Whereas K-Ras+/G12V;
Erk1+/+ mice (n = 17) displayed 50% survival at 40 weeks,
K-Ras+/G12V;Erk1/ animals (n = 14) reached this survival rate
at 46.3 weeks, a 20% increase taking into account that tumor
development was initiated when mice were 8 weeks old. We
obtained similar results when we ablated the locus encoding
the Erk2 kinase. Ad-Cre treated K-Ras+/G12V;Erk2 lox/lox mice
(n = 32) survived slightly longer than control K-Ras+/G12V;
Erk2+/+ (n = 19) animals (50% survival at 34.9 versus 31.2 weeks,
a 16% increase in survival) (Figure 1A). The difference in the time
at which control mice reached 50% survival is due to the intrinsic
variability of the different Ad-Cre preparations. Yet, because the
same viral preparation was used for all mice in each experiment,
the limited increase in survival observed in mice carrying the
targeted Erk alleles must be attributable to the absence of the
corresponding Erk kinase.
K-Ras+/G12V;Erk1/ and K-Ras+/G12V;Erk2 lox/lox mice sacri-
ficed 6 months after Ad-Cre infection displayed tumor burden
similar to those of control animals (Figure 1B). As expected,
Erk1 was absent from K-Ras+/G12V;Erk1/ NSCLCs. Likewise,
Erk2 could not be detected in lung tumors derived from
K-Ras+/G12V;Erk2 lox/lox mice (Figure 1C) due to efficient excision
of the Erk2 lox alleles (see Figure S1 available online). Absence of
Erk1 or Erk2 did not result in increased expression of theCancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc. 653
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Figure 2. Complete Ablation of Erk1/2 Kinases Prevents Induction of
NSCLCs by a Resident K-RasG12V Oncogene
(A)Survival ofK-Ras+/G12V;Erk1+/+;Erk2+/+ (n=14) (opencircles) andK-Ras+/G12V;
Erk1/;Erk2 lox/lox (n = 11) (solid circles) mice treated with Ad-Cre at 8 weeks of
age.
(B) Whole-mount X-Gal staining of lung sections collected from mice with
the indicated genotypes 6 months after Ad-Cre treatment. b-Geo positive
cells identified by X-Gal staining (blue color) correspond to cells expressing
K-RasG12V. Scale bars, 5 mm.
(C) Number of tumors, classified by grade (I–IV), observed in K-Ras+/G12V;
Erk1+/+;Erk2+/+ (n = 7) (open bars) and K-Ras+/G12V;Erk1/;Erk2 lox/lox (n = 10)
(solid bars) mice sacrificed 6 months after Ad-Cre treatment. Error bars indi-
cate mean ± SD. p values were calculated according to Student’s t test.
(D) The top panel shows Southern blot analysis of genomic DNA isolated
from individual tumors of K-Ras+/G12V;Erk1/;Erk2 lox/lox mice 8 months after
Ad-Cre treatment. DNAs were digested with KpnI and probed with a 450 bp
DNA fragment derived from the third intron just outside the floxed sequences.
Migration of the unrecombined Erk2 lox allele (4.3 kbp) and the ablated Erk2
allele (2.4 kbp) is indicated by arrowheads. The bottom panel shows western
blot analysis of Erk1 and Erk2 expression in lysates obtained from individual
tumors collected 8 months after Ad-Cre treatment of K-Ras+/G12V;Erk1+/+;
Erk2+/+ and K-Ras+/G12V;Erk1/;Erk2 lox/lox mice. The presence of Erk2 in
tumors of Ad-Cre treated K-Ras+/G12V;Erk1/;Erk2 lox/lox mice, due to
incomplete cleavage of the Erk2 lox allele, indicates that Erk2 is essential for
tumor development. Gapdh was used as loading control. Migration of the
above proteins is indicated by arrowheads.
(E) Survival of Erk1+/+;Erk2+/+;RERTert/ert (open circles) and Erk1/;Erk2 lox/lox;
RERT ert/ert (solid circles) mice fed ad libitum a tamoxifen-containing diet to
activate the knocked in CreERT2 recombinase encoded by theRERTert alleles.
See also Figure S2.
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c-Raf, A Therapeutic Target for K-Ras-Driven NSCLCremaining kinase (Figure 1C). Likewise, the levels of pErk2 were
the same in the presence or absence of Erk1, although the levels
of pErk1were slightly elevated in the absence of Erk2 (Figure 1C).654 Cancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc.Finally, the phosphorylation levels of Rsk, a well-known Erk
downstream substrate, did not change upon elimination of either
Erk1 or Erk2 (Figure 1C). These observations suggest that
a single Erk kinase, either Erk1 or Erk2, is sufficient to process
K-RasG12V oncogenic signaling to initiate NSCLC development.
Elimination of Erk1/2 Kinases Impairs Tumor
Development and Induces Lethality in Adult Mice
To evaluate the effect of eliminating both Erk kinases in
K-RasG12V-driven tumors, we generated K-Ras+/G12V;Erk1/;
Erk2 lox/lox mice and exposed their lungs to Ad-Cre infection.
Control K-Ras+/G12V;Erk1+/+;Erk2+/+ animals (n = 14) displayed
a 50% survival at 48 weeks. Instead, the 50% survival point for
K-Ras+/G12V;Erk1/;Erk2 lox/lox mice (n = 11) was reached at
63 weeks (Figure 2A), thus representing a 40% increase
in survival. When we examined K-Ras+/G12V;Erk1/;
Erk2 lox/lox mice 6 months after turning on K-RasG12V expression,
we observed very few tumors compared to control animals
(Figures 2B and 2C). More importantly, all tumors tested (n = 6)
displayed a prominent band corresponding to the nonrecom-
bined Erk2 lox allele and expressed normal levels of Erk2,
indicating that these tumors were ‘‘escapers’’ (Figure 2D). These
observations indicate that Erk2 is required for tumor develop-
ment in the absence of Erk1.
Next, we examined whether Erk1/2 kinases might be required
for normal homeostasis. To this end we generated Erk1/;
Erk2 lox/lox;RERTert/ert mice. RERTert mice ubiquitously express
an inducible CreERT2 recombinase (Guerra et al., 2003).
Thirty-day-old Erk1/;Erk2 lox/lox;RERTert/ert mice were fed ad
libitum with a tamoxifen-containing diet to systemically excise
the Erk2 lox alleles. The health of these mice (n = 8) deteriorated
rapidly, and all of them died within 3 weeks due to multiple organ
failure (Figure 2E). DNA analysis of tissues obtained from mori-
bund animals revealed recombination rates of the Erk2 lox alleles
ranging from 40% to 60% (Figure S2). These observations indi-
cate that loss of Erk proteins is incompatible with life in adult
mice. Interestingly, preliminary results indicate that a single Erk
allele is sufficient to maintain adult homeostasis because
Erk1/;Erk2+/lox;RERTert/ert (n = 2) and Erk1+/;Erk2 lox/lox;
RERTert/ert (n = 3) mice exposed to a tamoxifen diet for 3 months
did not show significant abnormalities (data not shown).
Individual Mek1/2 Kinases Are Dispensable
for K-RasG12V-Driven NSCLCs
We also evaluated the effect of eliminating the Mek1/2 kinases
on tumor development. To this end we used Mek1lox/lox (Catala-
notti et al., 2009) and Mek2/ (Belanger et al., 2003) strains
since Mek1, but not Mek2, is required for survival during
embryonic development (Giroux et al., 1999; Belanger et al.,
2003; Bissonauth et al., 2006). Survival of Ad-Cre treated
K-Ras+/G12V; Mek1lox/lox mice (n = 14) was slightly increased
(50% survival at 44 versus 37.5 weeks in control mice [n = 20],
a 22% increase) (Figure 3A). Similar results were observed with
K-Ras+/G12V;Mek2/ mice (n = 19) (50% survival at 52 versus
45 weeks in control animals [n = 20], a 19% increase) (Figure 3A).
When these mice were sacrificed 6 months after exposure
to Ad-Cre, they displayed a similar tumor burden as control
animals carrying wild-type Mek alleles (Figure 3B). Southern blot
analysis of individual tumors isolated from K-Ras+/G12V;
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Figure 3. K-RasG12V Induces NSCLCs in the Absence of Mek1 or
Mek2
(A) The left panel shows survival of K-Ras+/G12V;Mek1+/+ (n = 20) (open circles)
and K-Ras+/G12V;Mek1lox/lox (n = 14) (solid circles) mice treated with Ad-Cre
at 8 weeks of age. The right panel illustrates survival of K-Ras+/G12V;Mek2+/+
(n = 20) (open circles) and K-Ras+/G12V;Mek2/ (n = 19) (solid circles) mice
treated with Ad-Cre at 8 weeks of age.
(B) The left panel shows the number of tumors, classified by grade (I–IV),
observed inK-Ras+/G12V;Mek1+/+ (n = 7) (open bars) andK-Ras+/G12V;Mek1lox/lox
(n = 6) (solid bars) mice sacrificed 6 months after Ad-Cre treatment. The right
panel illustrates the number of tumors, classified by grade (I–IV), observed in
K-Ras+/G12V;Mek2+/+ (n = 5) (open bars) and K-Ras+/G12V;Mek2/ (n = 5) (solid
bars) mice sacrificed 6 months after Ad-Cre treatment. Error bars indicate
mean ± SD. p values were calculated according to Student’s t test.
(C) Western blot analysis of pMek, Mek1, Mek2, pErk1/2, and Erk1/2
expression in lysates derived from individual tumors of the indicated genotype
collected 8 months after Ad-Cre treatment. Gapdh was used as loading
control. Migration of the above proteins is indicated by arrowheads.
See also Figure S3.
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c-Raf, A Therapeutic Target for K-Ras-Driven NSCLCMek1lox/loxmice revealed thatMek1lox alleles had undergone effi-
cient recombination (Figure S3). Indeed, the levels of expression
of Mek1 in these tumors were almost undetectable (Figure 3C).
As expected, Mek2 could not be detected in tumors isolated
from K-Ras+/G12V;Mek2/ animals (Figure 3C).
As previously observed with Erk kinases, loss of Mek1 did not
result in increased Mek2 expression (Figure 3C). Likewise, the
levels of Mek1 were similar in tumors derived from Mek2/
and Mek2+/+ control mice. No changes were observed in the
levels of pMek proteins in those tumors generated in the
absence of Mek1 or Mek2 (Figure 3C). Finally, loss of one ofthe two Mek kinases had no significant effect on overall Mek
activity, as determined by the normal phosphorylation levels dis-
played by their downstream targets, Erk1/2 (Figure 3C).
Mek1/2 Kinases Are Essential for Tumor Development
and Normal Homeostasis
To determine whether both Mek kinases were required for
NSCLC, we exposed K-Ras+/G12V;Mek1lox/lox;Mek2/ mice to
Ad-Cre. These mice displayed significantly increased survival
when compared with control K-Ras+/G12V;Mek1+/+;Mek2+/+
animals. Whereas the control cohort (n = 10) had a 50% survival
rate of 33 weeks, K-Ras+/G12V;Mek1lox/lox;Mek2/ mice (n = 14)
had a 50% survival rate at 57 weeks (Figure 4A), thus displaying
an almost 100% increase in survival. As illustrated in the case of
the Erk kinases, tumors present in K-Ras+/G12V;Mek1lox/lox;
Mek2/ mice examined 6 months after Ad-Cre treatment (n =
6) carried unrecombined Mek1lox alleles and expressed normal
levels of Mek1 (Figures 4B and 4C). These observations indicate
that Mek1 expression was essential for tumor development in
the absence of Mek2 (Figure 4D).
To examine whether Mek kinase activity was essential for
adult homeostasis, Mek1lox/lox;Mek2/;RERTert/ert mice were
exposed to a tamoxifen diet at 30 days of age. These mice (n =
6) also displayed a rapid deterioration of their health, leading to
death just 2 weeks after starting the tamoxifen diet (Figure 4E).
Southern blot analysis of DNA isolated from tissues of sick/mori-
bund animals revealed recombination rates of Mek1lox alleles
ranging from 70% to 80% in most tissues (Figure S4A). These
observations indicate that the Mek kinases are also essential
for adult homeostasis. Whether a singleMek allele might be suffi-
cient to sustain adult life remains to be determined.
Necropsy analysis of moribund mice reveled multiple defects,
including severe alterations in the structure of intestinal and
colonic tissue incompatible with life (Figure S4B). Even limited
ablation of Mek alleles resulted in significant alterations of the
normal architecture, including distorted crypts, blunted and
shorter villi, increased lamina propria, and goblet cell hyper-
plasia. Likewise, the colonic tissue of Mek1lox/lox;Mek2/;
RERTert/ert mice displayed loss as well as severe shortening of
the crypts (Figure S4B).
B-Raf Is Dispensable for K-RasG12V-Induced NSCLCs
Raf kinases—A-Raf, B-Raf, and c-Raf—do not have full
compensatory activities during embryonic and early postnatal
development (Galabova-Kovacs et al., 2006). To examine
whether they also played unique roles during K-RasG12V-driven
NSCLC, we crossed K-Ras+/G12V mice with B-Raf lox/lox (Chen
et al., 2006) and c-Raf lox/lox (Jesenberger et al., 2001) animals
and submitted them to infection with Ad-Cre particles. As illus-
trated in Figure 5A, conditional ablation of B-Raf lox alleles in
K-RasG12V-induced NSCLC did not increase survival (50%
survival of K-Ras+/G12V;B-Raf lox/lox mice [n = 25] at 41.5 versus
40 weeks in K-Ras+/G12V;B-Raf+/+ control animals [n = 28],
a 5% increase). The number and grade of tumors in mice lacking
B-Raf 6 months after Ad-Cre treatment were similar to those
present in control mice (Figures 5B and 5C). Efficient recombina-
tion of the B-Raf lox alleles in tumor tissue was determined by
Southern (Figure S5) and western (Figure 5D) blot analysis.
Immunohistochemistry staining with an anti-B-Raf antibodyCancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc. 655
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Figure 5. B-Raf Is Not Required for K-Ras+/G12V-Induced NSCLCs in
Mice
(A) Survival of K-Ras+/G12V;B-Raf +/+ (n = 28) (open circles) and K-Ras+/G12V;
B-Raf lox/lox (n = 25) (solid circles) mice treated with Ad-Cre at 8 weeks of age.
(B) Whole-mount X-Gal staining of lung sections collected from mice with the
indicated genotypes 6 months after Ad-Cre treatment. b-Geo positive cells
identified by X-Gal staining (blue color) correspond to cells expressing
K-RasG12V. Scale bars, 5 mm.
(C) Number of tumors, classified by grade (I–IV), observed in K-Ras+/G12V;
B-Raf +/+ (n = 5) (open bars) and K-Ras+/G12V;B-Raf lox/lox (n = 5) (solid bars)
mice. Error bars indicate mean ± SD. p values were calculated according to
Student’s t test.
(D) Western blot analysis of B-Raf, c-Raf, A-Raf, pMek, Mek1, pErk1/2, and
Erk1/2 expression in lysates derived from individual tumors of the indicated
genotype collected 8 months after Ad-Cre treatment. Gapdh was used as
loading control. Migration of the above proteins is indicated by arrowheads.
(E) Tumors retained phosphorylated Erk expression in the absence of B-Raf.
Hematoxylin and eosin (H&E) (left panels) and immunohistochemical staining
of consecutive paraffin-fixed sections using anti-B-Raf (center panels) and
anti-pErk (right panels) antibodies. Sections were obtained from lungs of
Ad-Cre treated K-Ras+/G12V;B-Raf +/+ (top panels) and K-Ras+/G12V;B-Raf lox/lox
(bottom panels) mice. Insets show detail of larger areas. Scale bars, 0.5 mm
(main field) and 0.02 mm (inset).
See also Figure S5.
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Figure 4. Elimination of Mek1/2 Kinases Prevents Induction of
NSCLCs by an Endogenous K-RasG12V Oncogene
(A) Survival of K-Ras+/G12V;Mek1+/+;Mek2+/+ (n = 10) (open circles) and
K-Ras+/G12V;Mek1lox/lox;Mek2/ (n = 14) (solid circles) mice treated with Ad-
Cre at 8 weeks of age.
(B) Whole-mount X-Gal staining of lung sections collected from mice with the
indicated genotypes 6 months after Ad-Cre treatment. b-Geo positive cells
identified by X-Gal staining (blue color) correspond to cells expressing
K-RasG12V. Scale bars, 5 mm.
(C) Number of tumors, classified by grade (I–IV), observed in K-Ras+/G12V;
Mek1+/+;Mek2+/+ (n = 6) (open bars) and K-Ras+/G12V;Mek1lox/lox;Mek2/ (n =
8) (solid bars) mice. Error bars indicate mean ± SD. p values were calculated
according to Student’s t test.
(D) The top panel shows Southern blot analysis of genomic DNA isolated from
individual tumors of K-Ras+/G12V;Mek1lox/lox;Mek2/mice 8 months after Ad-
Cre treatment. DNAs were digested with HindIII and probedwith a 680 bp DNA
fragment obtained from a region downstream from the second loxP site. The
migration of the unrecombined Mek1lox allele (1.7 kbp) and the Mek1– allele
(1.5 kbp) is indicated by arrowheads. The bottom panel shows western blot
analysis of Mek1 and Mek2 expression in lysates obtained from individual
tumors collected 8 months after Ad-Cre treatment of K-Ras+/G12V;Mek1+/+;
Mek2+/+ and K-Ras+/G12V;Mek1lox/lox;Mek2/ mice. The presence of Mek1 in
tumors of Ad-Cre treated K-Ras+/G12V;Mek1lox/lox;Mek2/mice, due to partial
cleavage of the Mek1lox allele, indicates that Mek1 is essential for tumor
development. Gapdh was used as loading control. Migration of the above
proteins is indicated by arrowheads.
(E) Survival ofMek1+/+;Mek2+/+;RERTert/ert (n = 6) (open circles) andMek1lox/lox;
Mek2/;RERT ert/ert (n = 6) (solid circles) mice fed ad libitum a tamoxifen-
containing diet to activate the knocked in CreERT2 recombinase encoded by
the RERTert alleles.
See also Figure S4.
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Figure 6. c-Raf Is Essential forK-Ras+/G12V-InducedNSCLCs inMice
(A) Survival of K-Ras+/G12V;c-Raf +/+ (n = 22) (open circles) and K-Ras+/G12V;
c-Raf lox/lox (n = 23) (solid circles) mice treated with Ad-Cre at 8 weeks of age.
(B) Whole-mount X-Gal staining of lung sections collected from mice with the
indicated genotypes 6 months after Ad-Cre treatment. b-Geo positive cells
identified by X-Gal staining (blue color) correspond to cells expressing
K-RasG12V. Scale bars, 5 mm.
(C) Number of tumors, classified by grade (I–IV), observed in K-Ras+/G12V;
c-Raf +/+ (n = 8) (open bars) and K-Ras+/G12V;c-Raf lox/lox (n = 8) (solid bars)
mice. Error bars indicate mean ± SD. p values were calculated according to
Student’s t test.
(D) The top panel shows Southern blot analysis of DNA isolated from individual
tumors obtained from K-Ras+/G12V;c-Raf lox/lox mice infected with Ad-Cre
particles at 8 weeks of age. Tumor DNAs were digested with PstI. The sizes of
the diagnostic DNA fragments for c-Raf lox and c-Raf alleles are indicated.
The bottom panel illustrates western blot analysis of c-Raf expression in
lysates obtained from individual tumors collected 8 months after Ad-Cre
treatment of K-Ras+/G12V;c-Raf +/+ and K-Ras+/G12V;c-Raf lox/lox mice. The
presence of c-Raf in tumors of Ad-Cre treated K-Ras+/G12V;c-Raf lox/lox mice is
due to incomplete cleavage of the c-Raf lox allele. These results indicate that c-
Raf is essential for tumor development. Gapdh was used as loading control.
Migration of the above proteins is indicated by arrowheads.
See also Figure S6.
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c-Raf, A Therapeutic Target for K-Ras-Driven NSCLCfurther confirmed the absence of B-Raf expression in tumor
tissue (Figure 5E). Interestingly, elimination of B-Raf expression
had no effect on the levels of Mek and Erk phosphorylation, as
determined by either western blot (Figure 5D) or immunohisto-
chemical (Figure 5E) analysis. These observations suggest
that in the absence of B-Raf, other Raf proteins can maintainmitogenic signaling through theMek/Erk pathway. This compen-
satory effect did not involve increased expression of the other
Raf kinases (Figure 5D).
c-Raf Is Essential to Mediate Oncogenic Signaling
in K-RasG12V-Driven NSCLCs
Next, we investigated whether c-Raf kinase was also dispens-
able for K-RasG12V-driven NSCLCs. Ad-Cre treated K-Ras+/G12V;
c-Raf lox/lox mice survived significantly longer than the control
cohort. Whereas 50% of K-Ras+/G12V;c-Raf+/+ animals (n = 22)
had to be sacrificed by 38 weeks of age, half of K-Ras+/G12V;
c-Raf lox/lox mice (n = 23) were alive at 63 weeks. This difference
represents an 83% increase in survival (Figure 6A). As expected,
this increased survival was a direct consequence of the reduced
number of tumors present in K-Ras+/G12V;c-Raf lox/lox mice
6 months after Ad-Cre treatment (Figures 6B and 6C). More
importantly, each tumor tested (n = 11) retained c-Raf lox alleles
(Figure 6D). These results were confirmed by western blot anal-
ysis of nine independent tumors (Figure 6D). These observations
indicate that NSCLCs driven by K-RasG12V cannot develop in the
absence of c-Raf and that the tumors responsible for the death of
the K-Ras+/G12V;c-Raf lox/lox mice must be ‘‘escapers,’’ as previ-
ously observed in mice lacking Erk1/2 and Mek1/2 kinases.
Systemic Depletion of c-Raf and B-Raf Kinases
in Adult Mice Is Well Tolerated
To ascertain whether c-Raf expression was required for adult
tissues, we fed 30-day-old c-Raf lox/lox;RERTert/ert mice a tamox-
ifen diet for 3 months. Unlike mice deprived of Erk or Mek
expression, c-Raf lox/lox;RERTert/ert mice did not show loss of
body weight or decreased activity during this period of time.
None of the tissues obtained from mice sacrificed at the end of
the dietary treatment displayed obvious anatomical defects
(data not shown) despite efficient recombination of c-Raf lox
alleles in most organs (60%–100% excision) (Figure 7A). Brain
tissue served as a negative control because tamoxifen crosses
the blood-brain barrier rather inefficiently.
Available Raf kinase inhibitors display limited selectivity (Tsai
et al., 2008), suggesting that they may result in systemic inhibi-
tion of all Raf kinases. Because A-Raf conditional mutant mice
are not available, we investigated whether concomitant ablation
of B-Raf and c-Raf loci in adult mice had deleterious conse-
quences. B-Raf lox/lox;c-Raf lox/lox;RERTert/ert mice exposed to
a tamoxifen diet for 3 months remained healthy and did not
show weight loss or behavioral changes. Moreover, histological
examination of 20 different tissues at the end of the treatment did
not reveal detectable abnormalities (data not shown). These
tissues displayed efficient recombination of the B-Raf lox and/or
c-Raf lox alleles, ranging from 80% to 100% excision in the
case of B-Raf lox and 60% to 100% in the case of c-Raf lox (Fig-
ure 7B). Brain tissue served as a negative control.
Analysis of these tissues for the expression of A-Raf indicated
that this isoform is widely expressed, even in the absence of
B-Raf and c-Raf alleles, thus suggesting that A-Raf may
compensate for the absence of the other Raf isoforms (Fig-
ure S6). Interestingly, the levels of pMek and pErk showed signif-
icant variation from tissue to tissue. Yet, within a given tissue, we
did not observe significant variation in the levels of Mek and Erk
phosphorylation, regardless of the extent to which the B-Raf andCancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc. 657
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Figure 7. Adult Mice Tolerate Widespread
Ablation of B-Raf and c-Raf Alleles
(A) Southern blot analysis of DNA isolated from
tissues of c-Raf lox/lox;RERT ert/ert mice fed ad
libitum with a tamoxifen diet for 3 months (P30–
P120). DNA was digested with PstI and probed
with a 854 bp DNA fragment corresponding to
sequences located in intron 4 downstream from
the second loxP site. Migration of the ablated
c-Raf allele and the unrecombined c-Raf lox
allele is indicated by arrowheads. The sizes of
the diagnostic DNA fragments for these alleles
are also indicated. Whereas some tissues such
as testis (Te), ovaries (Ov), heart (Ht), and muscle
(Mu) display partial c-Raf lox cleavage (from 50%
to 70%), the majority of the tissues, including
lung (Lu), stomach (St), colon (Co), skin (Sk),
intestine (In), liver (Li), kidney (Ki), pancreas (Pa),
and spleen (Sp), showed complete or almost
complete excision. Brain tissue (Br) served as negative control because tamoxifen crosses the brain-blood barrier with limited efficiency.
(B) Southern blot analysis of DNA isolated from tissues of B-Raf lox/lox;c-Raf lox/lox;RERTert/ert mice fed ad libitum with a tamoxifen diet for 3 months (P30–P120).
DNA samples were digested with HindIII and probed with a 422 bp DNA fragment corresponding to sequences located in intron 12 upstream from the first loxP
site. Migration of the ablated B-Raf null (B-Raf) and c-Raf null (c-Raf) alleles as well as of the unrecombined B-Raf lox and c-Raf lox alleles is indicated by
arrowheads. The sizes of the diagnostic DNA fragments for these alleles are also indicated. The top panel shows B-Raf lox alleles that are almost completely
recombined in lung (Lu), stomach (St), colon (Co), kidney (Ki), pancreas (Pa), spleen (Sp), and thymus (Th) and only partially cleaved in testis (Te), ovaries (Ov), and
heart (Ht). The bottom panel illustrates c-Raf lox alleles that were partially excised in testis (Te), ovaries (Ov), heart (Ht), lung (Lu), stomach (St), and colon (Co) and
completely recombined in kidney (Ki), pancreas (Pa), spleen (Sp), and thymus (Th). Brain tissue (Br) served as negative control.
See also Figure S7.
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may explain the lack of defects observed in adult B-Raf lox/lox;
c-Raf lox/lox;RERTert/ert mice.
c-Raf Blocks K-Ras Oncogene Signaling in NSCLCs
by a Mechanism Other than Inducing Senescence
or Apoptosis
Next, we examined the mechanisms by which ablation of c-Raf
impaired tumor development in response to K-RasG12V signaling.
Expression of K-RasG12V in lung cells lacking Cdk4 induces an
immediate senescence response that prevents cell proliferation
(Puyol et al., 2010). However, lung sections of K-Ras+/G12V;
c-Raf lox/lox mice did not display detectable senescent cells
4 weeks after turning on K-RasG12V expression, as determined
by the absence of senescence-associated b-galactosidase
(SA-b-gal) staining (Figure S7A). Similar results were obtained
at an earlier time point of 2 weeks (data not shown). As a positive
control, sections from K-Ras+/G12V;Cdk4/ animals displayed
SA-b-gal positive cells (Figure S7A).
It has been described that c-Raf protects cells from apoptosis
(Mikula et al., 2001; Yamaguchi et al., 2004; Piazzolla et al., 2005;
Matallanas et al., 2007). Thus, we reasoned that in the absence
of c-Raf, K-RasG12V expression might lead to rapid apoptotic
death of lung cells. However, lung sections of K-Ras+/G12V;
c-Raf lox/lox mice taken 4 weeks after turning on K-RasG12V
expression did not display detectable levels of active Caspase
3 (Figure S7B). Similar results were obtained at earlier time points
(data not shown). These observations indicate that ablation of
c-Raf expression did not result in increased apoptosis.
We have also examined the fate of K-RasG12V expressing cells
uponablation ofc-Raf loxalleles. To this endwe took advantageof
the expression of b-Geo as a surrogate marker for the K-RasG12V
oncoprotein (Guerra et al., 2003). In this experiment, Cre recom-658 Cancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc.binase activity was provided by the RERTert/ert alleles instead of
Ad-Cre to avoid inducing an inflammatory response that may
interfere with detection of b-Geo expression. As illustrated in
Figure S7C, K-Ras+/G12V;c-Raf+/+;RERTert/ert and K-Ras+/G12V;
c-Raflox/lox;RERTert/ert mice displayed the same number of
K-RasG12V positive cells (based on the surrogate b-Geo expres-
sion) 15 days after 4OHT exposure, suggesting that loss of
c-Raf expression did not induce death of K-RasG12V-containing
lung cells. Moreover, the number of K-RasG12V positive cells
remained constant 2 weeks later despite lacking c-Raf. These
observations suggest that elimination of c-Raf does not result
in death of K-RasG12V-expressing lung cells.
We have recently shown that ablation of c-Raf in skin tumors
driven by constitutive activation of the Ras-GEF, SOS, resulted
in tumor disappearance due to increased terminal differentiation
of tumor cells (Ehrenreiter et al., 2009). These effects were
mediated by the synchronous activation of the Rok kinase
upon c-Raf ablation (Ehrenreiter et al., 2009). Unfortunately,
more than 30% of lung cells, regardless of genotype, had an
active Rok kinase, as determined by the presence of phosphor-
ylated Cofilin, a downstream target of this kinase (data not
shown). Thus, it was not possible to determine whether the
lack of proliferation of lung cells deprived of c-Raf was mediated
by Rok activation.
K-Ras Signals through B-Raf and c-Raf in Mouse
Embryonic Fibroblasts and in Human NSCLC Cell Lines
We have also explored whether the requirement of c-Raf for
K-RasG12V signaling was cell type dependent. Cultures of
primary MEFs from E13.5 K-Ras+/G12V;RERTert/ert embryos
carrying B-Raf lox and c-Raf lox alleles, either individually or in
combination (n = 3), were exposed to 4OHT for 5 days to activate
the resident CreERT2 recombinase to induce K-RasG12V
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Figure 8. B-Raf and c-Raf Are Not Essential for Proliferation and
Immortalization of Primary MEFs Driven by Wild-Type or Oncogenic
K-Ras Signaling
(A) Western blot analysis of B-Raf and c-Raf protein expression in primary MEFs
derived from (top panel) three independent K-Ras+/G12V;RERTert/ert, K-Ras+/G12V;
B-Raf lox/lox;RERTert/ert, K-Ras+/G12V;c-Raf lox/lox;RERTert/ert, and K-Ras+/G12V;
B-Raf lox/lox;c-Raf lox/lox;RERTert/ert embryos, and (bottom panel) three indepen-
dent K-Ras+/+;RERTert/ert, K-Ras+/+;B-Raf lox/lox;RERTert/ert, K-Ras+/+;c-Raf lox/lox;
RERTert/ert, and K-Ras+/+;B-Raf lox/lox;c-Raf lox/lox;RERTert/ert embryos. These
MEFswere incubated in DMEM supplemented with 10% FBS in the presence of
4OHT for 5 days to activate expressionof the residentK-Ras+/G12V oncogene and
to eliminate the c-Raf lox (c-RafD) and/or B-Raf lox (B-RafD) conditional alleles.
Gapdh served as loading control. Migration of the corresponding proteins is
indicated by arrowheads.
(B) Growth curves of the primary MEFs (n = 3) described above. MEFs
were grown in DMEM supplemented with 10% FBS and 600 nM 4OHT for
5 days before seeding. Results are shown in arbitrary absorbance units. Left
panel shows K-Ras+/G12V;RERTert/ert (solid circles), K-Ras+/G12V;B-RafD/D;
RERTert/ert (open squares),K-Ras+/G12V;c-RafD/D;RERTert/ert (open circles), and
K-Ras+/G12V;B-RafD/D;c-RafD/D;RERTert/ert (open triangles). Right panel
illustrates K-Ras+/+;RERTert/ert (solid circles), K-Ras+/+;B-RafD/D;RERTert/ert
(open squares), K-Ras+/+;c-RafD/D;RERTert/ert (open circles), and K-Ras+/+;
B-RafD/D;c-RafD/D;RERTert/ert (open triangles). Error bars indicate mean ± SD.
(C) The left panel shows western blot analysis of B-Raf and c-Raf protein
expression in primary MEFs derived from five independent K-Ras+/G12V;
B-Raf lox/lox;RERT ert/ert, K-Ras+/G12V;c-Raf lox/lox;RERT ert/ert, and K-Ras+/G12V;
B-Raf lox/lox;c-Raf lox/lox;RERT ert/ert embryos. Samples from two K-Ras+/G12V;
RERTert/ert embryos are also shown. MEFs were incubated in DMEM supple-
mentedwith 2%FBS in the presence of 4OHT for 5 days to activate expression
of the resident K-RasG12V oncogene and to eliminate the c-Raf lox (c-RafD) and/
or B-Raf lox (B-RafD) conditional alleles. Gapdh served as loading control.
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(Figure 8A). Inhibition of c-Raf expression partially decreased but
did not eliminate proliferation of K-RasG12V-expressing primary
MEFs (Figure8B).Similar resultswereobtainedwhenwe inhibited
B-Raf expression. Moreover, concomitant inhibition of both
proteinsdid not result in synergistic or additiveeffects (Figure 8B).
Similar results were obtained using limiting serumconditions (2%
fetal bovine serum [FBS]) (Figure 8C). The partial requirement of
B-Raf and c-Raf expression for proper proliferation was not
unique to MEFs expressing K-Ras oncogenes. In agreement
with previous observations, wild-type MEFs also required c-Raf
for optimal proliferation (Mikula et al., 2001). Elimination of c-Raf
and B-Raf, either alone or in combination, also resulted in partial
inhibition of their proliferative properties (Figure 8B).
We also examined whether B-Raf and c-Raf kinases were
required for immortalization of primary MEFs (Guerra et al.,
2003; Tuveson et al., 2004). Inhibition of B-Raf had little, if
any, effect on the immortalization rate of K-RasG12V-expressing
MEFs and did not induce proliferative senescence. Inhibition
of c-Raf, either alone or in combination with B-Raf, did not
affect the immortalization rate (Figure 8D). MEFs expressing
wild-type K-Ras underwent the expected proliferative senes-
cence. This process was exacerbated by inhibition of c-Raf,
but not of B-Raf (Figure 8D). However, these MEFs became
immortal after a few passages regardless of whether they
lacked c-Raf alone or c-Raf plus B-Raf. These results indicate
that neither B-Raf nor c-Raf proteins are essential for prolifera-
tion or immortalization of MEFs, regardless of whether they ex-
pressed normal or oncogenic K-Ras proteins.
Finally, we examined the effect of knocking down c-RAF and
B-RAF expression in human NSCLC cell lines containing
K-RAS oncogenes. To this end we selected four cell lines,
A549, H23, H358, and H441, of which only the last two have
shown a strong dependency (‘‘addiction’’) on K-RAS oncogenes
(Singh et al., 2009). As illustrated in Figure S8, the extent of ERK
phosphorylation was not significantly affected by knock down of
c-RAF or B-RAF expression. However, inhibition of c-RAF or
B-RAF affected their proliferation rate, although this inhibition
appeared to be unrelated to the relative addiction of these cell
lines to K-RAS oncogene expression. Moreover, as illustrated
above for MEFs, knock down of c-RAF and B-RAF had a similar
inhibitory effect on the proliferation rate of each of the respective
NSCLC cell lines (Figure S8). These observations indicate
that the exquisite requirement for c-Raf expression observed in
the K-RasG12V-driven NSCLC tumor model reported here might
not be a general property of K-Ras signaling. Alternatively,
inhibition of c-Raf and B-Raf expression may have different
consequences under in vitro growth conditions.Migration of the corresponding proteins is indicated by arrowheads. The right
panel shows growth curves of the primary MEFs (n = 5) described above.
MEFs were grown in DMEM supplemented with 2% FBS and 600 nM 4OHT.
K-Ras+/G12V;RERTert/ert (solid circles), K-Ras+/G12V;B-RafD/D;RERTert/ert (open
squares), K-Ras+/G12V;c-RafD/D;RERT ert/ert (open circles), and K-Ras+/G12V;
B-RafD/D;c-RafD/D;RERT ert/ert (open triangles). Error bars indicate mean ± SD.
(D) Immortalization of the primary MEFs described in (B) following a 3T3
protocol (n = 3). Cells were cultivated in DMEM supplemented with 10% FBS
and 600 nM 4OHT. Symbols are those described in (B). Error bars indicate
mean ± SD.
See also Figure S8.
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K-RAS oncogenes signal through a cascade of downstream
effectors, most of which are druggable kinases. Yet, to our
knowledge, there are no approved targeted therapies to treat
K-RAS-driven NSCLC. This situation may stem from our limited
knowledge of what effectors are directly responsible for medi-
ating K-RAS signaling in this tumor type and, hence, serve as
effective therapeutic targets. As illustrated in this study, each
one of the two Erk kinases, Erk1 or Erk2, is sufficient to allow initi-
ation of K-Ras-induced NSCLC. However, K-Ras oncogenes
could not transform lung cells in the absence of both Erk kinases.
Unfortunately, widespread loss of the Erk1/2 kinases resulted in
severe toxicity that led to the rapid death of the animal even
when only a limited percentage of cells (ranging from 40% to
60% depending on the tissue type) lost both Erk kinases. Yet,
a single Erk allele was sufficient to sustain normal adult homeo-
stasis. Hence, limited inhibition of ERK kinase activity within
a tolerated therapeutic window may provide a successful phar-
macological approach to treat K-RAS-positive NSCLC.
Similar results were observed when we targeted the Mek
kinases. Both Mek1 and Mek2 efficiently sustained K-Ras
oncogenic signaling in the absence of the other isoform. These
results differed from those observed with DMBA-induced skin
tumors in which Mek2 could not compensate for the absence
of Mek1 (Scholl et al., 2009), further illustrating that the
contribution of individual members of the Ras/Mek/Erk pathway
is likely to be cell type dependent. Moreover, complete loss of
Mek kinases prevented K-Ras-driven NSCLC development.
Unfortunately, as discussed above for their downstream Erk
kinases, widespread loss of Mek1/2 kinases was incompatible
with life. Dual MEK1/2 inhibitors have already been tested in
early-phase clinical trials. Early inhibitors including CI-1040,
AZD6244, and PD0325901 showed no significant antitumor
activity at the permissible doses in a series of solid tumors,
including advanced NSCLCs (Rinehart et al., 2004; Hainsworth
et al., 2010; Haura et al., 2010). Recently, a more potent MEK
inhibitor, GSK1120212, active on B-RAF-driven human mela-
noma cell lines (Villanueva et al., 2010), has yielded 2 partial
responses and 9 disease stabilizations in 14 patients suffering
from K-Ras oncogene-positive NSCLC (http://www.esmo.org/
events/milan-2010-congress). These results suggest that MEK
inhibition may yield therapeutic benefit to patients with NSCLC.
The immediate Ras downstream effectors within the Raf/Mek/
Erk pathway are the Raf kinases, A-Raf, B-Raf, and c-Raf. B-Raf
was completely dispensable for K-Ras oncogenic signaling, at
least within the context of NSCLC. Moreover, phosphorylation
of Erk proteins within the tumor appeared to be unaffected,
suggesting that other Raf kinases mediate K-Ras oncogenic
signaling in the absence of B-Raf. However, in this case the
compensatory effects of c-Raf (and/or A-Raf) on B-Raf were
not reciprocal. Elimination of c-Raf from K-RasG12V-expressing
lung cells completely inhibited tumor development. Thus, neither
B-Raf nor A-Raf could compensate for the lack of c-Raf.
Because K-Ras is the Ras isoform that binds and activates
c-Raf more efficiently (Voice et al., 1999), it is possible that
c-Raf might be essential to mediate K-Ras signaling to the Mek
and Erk kinases, at least in an oncogenic setting. Indeed, onco-
genic RAS exclusively signaled via c-RAF to the ERK-MAPK660 Cancer Cell 19, 652–663, May 17, 2011 ª2011 Elsevier Inc.pathway in human melanoma cell lines (Dumaz et al., 2006).
However, it is also possible that c-Raf, but not B-Raf or A-Raf,
may modulate an alternative downstream pathway essential for
malignant transformation (Takezawa et al., 2009), but not for
normal homeostasis. This hypothesis may also help to explain
why elimination of c-Raf is not deleterious for adult mice.
The existence of c-Raf-dependent, Mek-independent path-
ways in K-Ras oncogene-induced tumors has been invoked
before (Haigis et al., 2008). More recently, such a pathway has
been shown to be essential for the development and mainte-
nance of Ras-driven epidermal tumors (Ehrenreiter et al.,
2009). In particular, loss of c-Raf in established tumors express-
ing a membrane-tagged SOS exchange factor induced
a massive increase in terminal differentiation of the tumor cells
accompanied by a sharp decline in cell proliferation, two events
that resulted in tumor regression. Terminal differentiation of
these SOS-expressing keratinocytes in the absence of c-Raf
was mediated by activation of the Rok pathway (Ehrenreiter
et al., 2009), a pathway that is normally inhibited by c-Raf via
direct interaction with Rok (Niault et al., 2009). Unfortunately,
the limited number of K-RasG12V-expressing cells and their
inability to expand in the absence of c-Raf made it impossible
for us to investigate the molecular events that prevent tumor
development. If c-Raf mediates K-RasG12V signaling via
protein-protein interaction with Rok or other substrates, thera-
peutic intervention will require strategies other than inhibition
of c-Raf catalytic activity. Recent studies have suggested that
different mutations in K-RAS may result in different clinical
outcomes (De Roock et al., 2010). Whether these differences
may result from different interactions with Ras effectors remains
to be determined.
RAF inhibitors with activity against B-RAF and c-RAF kinases
are potent inhibitors of tumors carrying a mutated B-RAFV600E
oncogene. However, these inhibitors activate the MEK-ERK
pathway in tumors carrying mutant K-RAS or wild-type RAS/
RAF molecules by a mechanism involving transactivation of
one protomer in RAF homodimers and heterodimers (Hatzivassi-
liou et al., 2010; Poulikakos et al., 2010). Moreover, Heidorn et al.
(2010) have illustrated that a kinase-dead B-Raf induces mela-
nomas in the presence of an endogenous K-Ras oncogene.
Finally, patients with melanoma treated with B-RAF inhibitors
develop cutaneous squamous cell carcinomas at significant
frequency (Bollag et al., 2010; Flaherty et al., 2010). Whether
similar results will be observed with c-RAF selective inhibitors
remains to be determined. Current efforts aimed at generating
mice expressing an inducible kinase-dead c-Raf protein may
also help to shed some light on this issue.
Recently, the use of synthetic lethal approaches with K-Ras-
driven NSCLC mouse tumor models has allowed the identifica-
tion of novel therapeutic targets, including the NF-kB pathway
and Cdk4 (Meylan et al., 2009; Puyol et al., 2010). Ablation of
Cdk4 expression in K-Ras oncogene containing lung cells eli-
cited an immediate senescence response that prevented tumor
initiation and progression (Puyol et al., 2010). Such response did
not appear to be responsible for the lack of proliferation of K-Ras
oncogene expressing cells in the absence of c-Raf. Thus, it is
possible that c-Raf and Cdk4 inhibitors may inhibit proliferation
of NSCLC cells by different mechanisms, thus resulting in syner-
gistic antitumor effects.
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address the effect of inhibiting these downstream effectors on
tumormaintenance rather than on tumor development. Replace-
ment of the Cre-lox strategy used in this study to activate
K-RasG12V expression by the Flpe-frt recombinase system will
allow temporal separation of tumor initiation and therapeutic
intervention. Results derived from these studies are likely to
provide more relevant information toward the development of
effective targeted therapies for the treatment of K-Ras onco-
gene-driven NSCLC.
EXPERIMENTAL PROCEDURES
Mice
K-Ras+/LSLG12Vgeo (Guerra et al., 2003), RERTert/ert (Guerra et al., 2003),
Erk1/ (Page`s et al., 1999), Erk2 lox/lox (Fischer et al., 2005),Mek1lox/lox (Cata-
lanotti et al., 2009), Mek2/ (Belanger et al., 2003), B-Raf lox/lox (Chen et al.,
2006), and c-Raf lox/lox (Jesenberger et al., 2001) strains have been previously
described. All animal experiments were approved by the Ethical Committee of
the CNIO and performed in accordance with the guidelines stated in the Inter-
national Guiding Principles for Biomedical Research Involving Animals, devel-
oped by the Council for International Organizations of Medical Sciences
(CIOMS). All strains were genotyped by Transnetyx (Cordova, TN, USA).
Adenovirus Intratracheal Infection
Eight to 10-week-old mice were treated once by intratracheal adeno-Cre
instillation with 2.5 3 108 pfu/mouse of virus after anesthesia (i.p. injection of
ketamine 75 mg/kg, xylazine 12 mg/kg) (Simpson et al., 2001).
Histopathology and Immunohistochemistry
For routine histological study, lung lobes were fixed in 10% buffered formalin
(Sigma) and embedded in paraffin. For quantification and classification of
tumor lesions, lung lobes were processed for whole-mount X-Gal staining to
detect b-Geo, as a surrogate marker for K-RasG12V expression (Guerra et al.,
2003). Stained tissues were embedded in paraffin, serially sectioned, and
tumors counted and classified according to standard histopathological
grading (Jackson et al., 2005). Antibodies used for immunostaining included
those raised against: B-Raf (Abcam; ab33899); pErk (Cell Signaling Tech-
nology; 9101); pCofilin (Santa Cruz Biotechnology; sc-21867-R); and active
Caspase3 (R&D Systems; AF835). For endogenous SA-b-gal detection, lung
lobes were snap-frozen in O.C.T. (Sakura) and processed on 10 mm cryostat
sections with a SA-b-gal staining kit (Cell Signaling Technology) in accordance
with the manufacturer’s recommendations. Counterstaining of cryostat
sections was performed with nuclear fast red.
Western Blot Analysis
Thirty micrograms of protein extracts obtained from either tumor tissue or
cell extracts were separated on SDS/PAGE gels (Bio-Rad), transferred to
a nitrocellulose membrane, and blotted with antibodies raised against B-Raf
(Santa Cruz Biotechnology; sc-5284), c-Raf (BD Biosciences; 610151),
A-Raf (Abcam; ab19880), Mek1 (Santa Cruz Biotechnology; sc-219), Mek2
(BD Biosciences; 610235), pMek (Cell Signaling Technology; 9154), Erk (Santa
Cruz Biotechnology; sc-93), pErk (Cell Signaling Technology; 9101), Rsk
(Santa Cruz Biotechnology; sc-231), pRsk (Cell Signaling Technology; 9341),
and Gapdh (Sigma; G8795). Primary antibodies were detected with goat
secondary antibodies directed against mouse or rabbit IgGs (Alexa Fluor
680; Invitrogen) and visualized with Odyssey Infrared Imaging System (LI-COR
Biosciences).
Cell Culture Assays
MEFs were isolated from E13.5 embryos and propagated according to stan-
dard 3T3 protocols. All experiments were carried out in the presence of
600 nM 4OHT (Sigma). For proliferation assays, MEFs were treated for
5dayswith 4OHT to ablate the conditionalB-Raf loxand c-Raf loxalleles, seeded
on 96-well plates (1000 cells/well) in triplicate in DMEM supplemented with
10% FBS, and their growth rate was determined by the MTT cell proliferationkit (Roche). Human NSCLC cell lines were purchased from the ATCC. Cells
were infectedwithMISSIONshRNAsdirected against B-RAFor c-RAF (Sigma).
Scrambled shRNA was used as control. Cells were selected with puromycin
(2 mg/ml) for 5 days before seeding. For proliferation assays cells were seeded
on 96-well plates (1000 cells/well) in RPMI medium supplemented with 10%
FBS and puromycin, and their growth rate was determined by the MTT cell
proliferation kit.
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